Recently, it has been suggested that GnRH antagonist administration in the luteal phase in patients with established severe early OHSS appears to prevent patient hospitalization and to result in quick regression of the syndrome on an outpatient basis. The gene discussed is GNRH1; the disease is ovarian hyperstimulation syndrome.